Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024. Which stocks will surge next?Unlock AI-picked Stocks

Kinnate Biopharma Inc (KNTE)

NASDAQ
Currency in USD
Disclaimer
2.65
0.00(0.00%)
Closed
KNTE Scorecard
Earnings results expected in 14 days
Fair Value
Unlock Value
Day's Range
2.642.67
52 wk Range
1.046.00
Prev. Close
2.65
Open
2.65
Day's Range
2.64-2.67
52 wk Range
1.04-6
Volume
0
Average Vol. (3m)
408,739
1-Year Change
1.34%
Shares Outstanding
47,225,312
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More

People Also Watch

0.7838
ACHL
+0.35%
10.22
ACNT
+1.79%
12.29
WSBF
+6.41%
2.140
CIA
+3.38%
How do you feel today about KNTE?
Vote to see community's results!
or

Kinnate Biopharma Inc Company Profile

Kinnate Biopharma Inc., a precision oncology company, focuses on the discovery, designing, and development of small molecule kinase inhibitors for treating genomically defined cancers in the United States. It develops KIN-3248, a fibroblast growth factor receptors (FGFR) inhibitor, for the treatment of patients with intrahepatic cholangiocarcinoma and urothelial carcinoma, and other solid tumors; and small molecule programs, including KIN-7136, a MEK inhibitor, as well as KIN-8741, an c-MET inhibitor with broad mutational coverage across a variety of solid tumors; and KIN-7324, a cyclin-dependent kinase 4 inhibitor. The company was incorporated in 2018 and is based in San Diego, California. Kinnate Biopharma Inc. operates as a subsidiary of XOMA Corporation.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.